Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone212-733-2323
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$53.65 billion
Profitability
Miscellaneous
Employees92,400
Next Earnings Date10/29/2019 (Estimated)
OptionableOptionable
Pfizer (NYSE:PFE) Frequently Asked Questions
What is Pfizer's stock symbol?
Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."
How often does Pfizer pay dividends? What is the dividend yield for Pfizer?
Pfizer declared a quarterly dividend on Thursday, June 27th. Investors of record on Friday, August 2nd will be given a dividend of $0.36 per share on Tuesday, September 3rd. This represents a $1.44 annualized dividend and a yield of 4.10%. The ex-dividend date of this dividend is Thursday, August 1st. View Pfizer's Dividend History.
How will Pfizer's stock buyback program work?
Pfizer declared that its Board of Directors has approved a stock buyback program on Friday, December 14th 2018, which authorizes the company to buyback $10,000,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to reacquire up to 3.8% of its shares through open market purchases. Shares buyback programs are generally a sign that the company's board believes its shares are undervalued.
How were Pfizer's earnings last quarter?
Pfizer Inc. (NYSE:PFE) posted its quarterly earnings results on Monday, July, 29th. The biopharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.75 by $0.05. The biopharmaceutical company had revenue of $13.26 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 28.10% and a net margin of 23.58%. The company's revenue for the quarter was down 1.5% on a year-over-year basis. During the same quarter last year, the business posted $0.77 EPS. View Pfizer's Earnings History.
When is Pfizer's next earnings date?
What guidance has Pfizer issued on next quarter's earnings?
Pfizer updated its FY19 earnings guidance on Monday, July, 29th. The company provided EPS guidance of $2.76-2.86 for the period, compared to the Thomson Reuters consensus estimate of $2.91. The company issued revenue guidance of $50.5-52.5 billion, compared to the consensus revenue estimate of $53.45 billion.
What price target have analysts set for PFE?
16 analysts have issued 1 year price objectives for Pfizer's shares. Their forecasts range from $40.00 to $55.00. On average, they anticipate Pfizer's stock price to reach $46.6667 in the next year. This suggests a possible upside of 33.0% from the stock's current price. View Analyst Price Targets for Pfizer.
What is the consensus analysts' recommendation for Pfizer?
16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 12 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Pfizer.
What are Wall Street analysts saying about Pfizer stock?
Here are some recent quotes from research analysts about Pfizer stock:
- 1. According to Zacks Investment Research, "Pfizer expects continued strong growth of key product franchises, including Ibrance, Eliquis, Xeljanz and Xtandi in 2019. However, loss of exclusivity on key drugs in the United States., mainly Lyrica and currency headwinds are expected to significantly hurt its 2019 sales. Other top-line headwinds are weak sales in the EH segment, pricing pressure and rising competition. To offset the threat of generic competition, Pfizer is strengthening its pipeline as well as oncology portfolio. Pfizer looks well positioned to deliver several potential new breakthrough innovative medicines in the next five years, which can drive long-term growth. Biosimilars are also expected to contribute to growth in 2019. Shares have underperformed the industry this year so far. Estimates have gone down slightly ahead of Q1 earnings release. Pfizer has a positive record of earnings surprises in recent quarters." (4/10/2019)
- 2. Cantor Fitzgerald analysts commented, "We reiterate our OW rating and think respectable earnings growth, driven by Innovative Medicines, pipeline advancements, and return of capital to PFE’s shareholders — above the industry average — are all underappreciated. Therefore, we believe multiple expansion and upward earnings revisions should drive PFE shares higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $53." (2/19/2019)
Has Pfizer been receiving favorable news coverage?
News coverage about PFE stock has been trending positive on Thursday, according to InfoTrie. The research firm scores the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Pfizer earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the stock's share price in the next few days. View News Stories for Pfizer.
Are investors shorting Pfizer?
Pfizer saw a increase in short interest during the month of July. As of July 31st, there was short interest totalling 67,951,100 shares, an increase of 17.7% from the June 30th total of 57,720,500 shares. Based on an average daily trading volume, of 24,920,000 shares, the short-interest ratio is currently 2.7 days. Currently, 1.2% of the shares of the company are sold short. View Pfizer's Current Options Chain.
Who are some of Pfizer's key competitors?
Some companies that are related to Pfizer include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Novartis (NVS), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AstraZeneca (AZN), Eli Lilly And Co (LLY), Sanofi (SNY), GlaxoSmithKline (GSK), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG) and Zoetis (ZTS).
What other stocks do shareholders of Pfizer own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Pfizer investors own include AT&T (T), Cisco Systems (CSCO), Johnson & Johnson (JNJ), General Electric (GE), Verizon Communications (VZ), Intel (INTC), Exxon Mobil (XOM), Bank of America (BAC), Merck & Co., Inc. (MRK) and Walt Disney (DIS).
Who are Pfizer's key executives?
Pfizer's management team includes the folowing people:
- Mr. Ian C. Read, Exec. Chairman (Age 65)
- Mr. Albert Bourla D.V.M., DVM, Ph.D., CEO & Director (Age 57)
- Mr. Frank A. D'Amelio, CFO & EVP of Global Supply & Bus. Operations (Age 61)
- Dr. Mikael Dolsten, Chief Scientific Officer & Pres of Worldwide Research, Devel. and Medical (Age 60)
- Mr. John D. Young, Group Pres & Chief Bus. Officer (Age 54)
Who are Pfizer's major shareholders?
Pfizer's stock is owned by a number of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.01%), Price T Rowe Associates Inc. MD (1.69%), Northern Trust Corp (1.37%), Bank of New York Mellon Corp (1.06%), Morgan Stanley (0.84%) and Fisher Asset Management LLC (0.79%). Company insiders that own Pfizer stock include Alexander R Mackenzie, Charles H Hill, Dawn Rogers, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Pfizer Inc, Rady A Johnson, Sally Susman and W Don Cornwell. View Institutional Ownership Trends for Pfizer.
Which institutional investors are selling Pfizer stock?
PFE stock was sold by a variety of institutional investors in the last quarter, including Barrow Hanley Mewhinney & Strauss LLC, Barrow Hanley Mewhinney & Strauss LLC, Price T Rowe Associates Inc. MD, Marshall Wace North America L.P., AQR Capital Management LLC, Quest Capital Management Inc. ADV, Vanguard Group Inc. and Acadian Asset Management LLC. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, Dawn Rogers, Douglas M Lankler, Frank A Damelio, Mikael Dolsten and Rady A Johnson. View Insider Buying and Selling for Pfizer.
Which institutional investors are buying Pfizer stock?
PFE stock was acquired by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Natixis, Natixis, Invesco Ltd., Thoroughbred Financial Services LLC, Railway Pension Investments Ltd, Fisher Asset Management LLC and Jensen Investment Management Inc.. View Insider Buying and Selling for Pfizer.
How do I buy shares of Pfizer?
Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pfizer's stock price today?
One share of PFE stock can currently be purchased for approximately $35.08.
How big of a company is Pfizer?
Pfizer has a market capitalization of $194.03 billion and generates $53.65 billion in revenue each year. The biopharmaceutical company earns $11.15 billion in net income (profit) each year or $3.00 on an earnings per share basis. Pfizer employs 92,400 workers across the globe.View Additional Information About Pfizer.
What is Pfizer's official website?
How can I contact Pfizer?
Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323.
MarketBeat Community Rating for Pfizer (NYSE PFE)
MarketBeat's community ratings are surveys of what our community members think about Pfizer and other stocks. Vote "Outperform" if you believe PFE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PFE will underperform the S&P 500 over the long term. You may vote once every thirty days.
